title: Systemic physostigmine increases the antinociceptive effect of spinal morphine.
abstract: In this study we evaluated the antinociceptive effect of concurrent intrathecal (i.t.) and subcutaneous (s.c.) administration of morphine and physostigmine, respectively. The experiments were performed on male Wistar rats. Intrathecal administration of morphine was performed through a catheter implanted in the subarachnoid space. The 'tail-immersion' test was used to measure animals' responses to evoked nociceptive stimuli. Interaction of drugs was analyzed using a dose addition model. Both i.t. (1-5 microg) administration of morphine and s.c. (50-250 microg/kg) administration of physostigmine increased the latencies of nociceptive responses in a dose-dependent manner. Two micrograms of i.t. morphine and 100 microg/kg of s.c. physostigmine demonstrated 31.6 +/- 10.6 and 34.2 +/- 11.4 percentage of maximal possible effect (%MPE), respectively. Simultaneous administration of 1 microg of i.t. morphine and 50 microg/kg of s.c. physostigmine produced a %MPE equal to 84.8 +/- 16.9. Thus, combined administration of 1 microg i.t. morphine and 50 microg/kg s.c. physostigmine resulted in a strong, highly significant antinociceptive effect. This effect was much higher than the effect expected if both drugs acted in an additive manner. Supra-additive interaction observed in this study might be a result of simultaneous activation of different neurotransmitter systems involved in nociceptive processing at the spinal as well as at the supraspinal level of the CNS.
authors.affiliation: Department of Anesthesiology, Rabin Medical Center, Golda Campus, Petach-Tikva, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Beilin
authors.forename: A Y
authors.initials: AY
authors.lastname: Nemirovsky
authors.forename: A
authors.initials: A
authors.lastname: Zeidel
authors.forename: E
authors.initials: E
authors.lastname: Maibord
authors.forename: V
authors.initials: V
authors.lastname: Zelman
authors.forename: R L
authors.initials: RL
authors.lastname: Katz
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007278:Injections, Spinal; D007279:Injections, Subcutaneous; D008297:Male; D009020:Morphine / Q000008:administration & dosage* / Q000627:therapeutic use; D009619:Nociceptors / Q000187:drug effects*; D010830:Physostigmine / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000701:Analgesics, Opioid; D002800:Cholinesterase Inhibitors; D009020:Morphine; D010830:Physostigmine